UBS Group’s Psyence Biomedical Warrant PBMWW Stock Holding History

UBS Group’s Portfolio PBMWW Stock Details PBMWW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-247	Closed	-$4	–	11133
2026 Q1	$4	Buy	+247	New	+$5	﹤0.01%	10367
2025 Q4	–	Sell	-455	Closed	-$11	–	11275
2025 Q3	$11	Buy	+455	New	+$11	﹤0.01%	10184
2025 Q2	–	Sell	-1,589	Closed	-$27	–	10925
2025 Q1	$27	Buy	+1,589	New	+$30	﹤0.01%	10063
2024 Q3	–	Sell	-73	Closed	-$1	–	10153
2024 Q2	$1	Hold	73	–	–	﹤0.01%	9441
2024 Q1	$5	Buy	+73	New	+$5	﹤0.01%	9143

Other funds holding PBMWW

HCI

Harraden Circle Investments New York $784M AUM 20.59% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

UBS Group's PBMWW Position: Q2 2026 in Review

UBS Group sold out of Psyence Biomedical Warrant (PBMWW) in Q2 2026, closing a stake of 247 shares — an estimated $4 sold.

UBS Group first reported a position in PBMWW in Q1 2024 and held it in 5 quarters. The position peaked at $27 in Q1 2025. 18 funds tracked by Wall St. Rank hold PBMWW as of Q2 2026.

UBS Group reported no remaining Psyence Biomedical Warrant position as of Q2 2026 after selling out during the quarter.
UBS Group sold 247 Psyence Biomedical Warrant shares in Q2 2026, an estimated $4.
UBS Group first reported a position in Psyence Biomedical Warrant in Q1 2024 and held it in 5 quarters.
UBS Group's Psyence Biomedical Warrant position peaked at $27 in Q1 2025.
18 funds tracked by Wall St. Rank held Psyence Biomedical Warrant as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.